Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Exopharm Limited
ABN	78 163 765 991

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Clarke Barlow
Date of last notice	1 December 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder)	N/A
Date of change	19 April 2024
No. of securities held prior to change	(1.1) 5,000,000 - UNLISTED DIRECTOR OPT @ \$0.015 EXP 01/12/2027
	(1.2) 2,500,000 - UNLISTED DIRECTOR OPT @ \$0.02 EXP 01/12/2027
	(1.3) 2,500,000 - UNLISTED DIRECTOR OPT @ \$0.03 EXP 01/12/2027
	(2) 20,000 - ORDINARY FULLY PAID SHARES
Class	(1.1) UNLISTED DIRECTOR OPT
	(1.2) UNLISTED DIRECTOR OPT
	(1.3) UNLISTED DIRECTOR OPT
	(2) ORDINARY FULLY PAID SHARES
Number acquired	Nil
Number disposed	Nil – reductions relate to the equal consolidation of the Company's share capital, being:
	(1.1) 3,000,000 - UNLISTED DIRECTOR OPT
	(1.2) 1,500,000 - UNLISTED DIRECTOR OPT
	(1.3) 1,500,000 - UNLISTED DIRECTOR OPT
	(2) 12,000 - ORDINARY FULLY PAID SHARES

⁺ See chapter 19 for defined terms.

^{01/01/2011} Appendix 3Y Page 1

Value/Consideration	N/A
No. of securities held after change	(1.1) 2,000,000 - UNLISTED DIRECTOR OPT @ \$0.0375 EXP 01/12/2027
	(1.2) 1,000,000 - UNLISTED DIRECTOR OPT @ \$0.05 EXP 01/12/2027
	(1.3) 1,000,000 - UNLISTED DIRECTOR OPT @ \$0.075 EXP 01/12/2027
	(2) 8,000 - ORDINARY FULLY PAID SHARES
Nature of change	Capital Reconstruction - Consolidation 2.5 : 1

Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Interest after change	N/A

Part 3 - +Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	N/A - Consolidation
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A